Results 211 to 220 of about 86,778 (305)

Beyond Traditional Risk Factors: Inflammation, Asymmetric Dimethylarginine, and N-Terminal pro-B-Type Natriuretic Peptide Predict Cardiovascular Risk in Chronic Kidney Disease. [PDF]

Cureus
Hoxha E, Collaku L, Kuka S, Seferi S, Pojani P, Habilaj X, Kambo M, Zaimi Petrela E, Bulo A, Resuli M.   +9 more
europepmc   +1 more source

Prevalence and Recovery of Arrhythmia‐Induced Cardiomyopathy in Patients With Newly Diagnosed Heart Failure Using a Wearable Defibrillator: A Real‐World Cohort Study

Journal of Cardiovascular Electrophysiology, EarlyView.
This graphical abstract summarizes the study design and main findings in patients with newly diagnosed left ventricular systolic dysfunction and concomitant arrhythmia undergoing early rhythm control under wearable cardioverter‐defibrillator protection.
Joerg Yogarajah, Jana Dannebaum, Ahmed Halim, Jamschid Sedighi, Matthias Mensch, Malte Kuniss, Thomas Neumann, Andreas Rieth, Julia Treiber, Samuel Sossalla, Andreas Hain   +10 more
wiley   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

Exploring the Prospective Insights Into the Prognostics of N-terminal Pro-B-Type Natriuretic Peptide in Predicting Heart Failure Readmissions in a Tertiary Healthcare Setting. [PDF]

Cureus
Shoaib GM, Shetty USA, Baloch MZ, Chaudry ZA.   +3 more
europepmc   +1 more source

Assessment of triglyceride‐glucose composite indices associated mortality risk in diabetes‐related heart failure

Journal of Diabetes Investigation, EarlyView.
Elevated TyG‐Age significantly increases the risk of heart failure in diabetic patients. Furthermore, combining TyG‐Age with the TRS‐HFDM score greatly enhances predictive capability and mortality risk assessment for these patients. ABSTRACT Background Patients with diabetes are at an increased risk of heart failure.
Qijie Zhao, Xiao Cai, Xing Wang, Jing Jin   +3 more
wiley   +1 more source

A Novel N-Terminal Pro-B-Type Natriuretic Peptide Assay in the Early Diagnosis of Acute Heart Failure. [PDF]

JACC Adv
Belkin M, Wussler D, Lopez-Ayala P, Nowak A, Gualandro DM, Sailova D, Popescu C, Strebel I, Niggemann M, Reinhardt J, Huré G, Kozhuharov N, Jenkins F, Kaplan E, Sgueglia F, Sabti Z, Chollet L, Rentsch K, Gawinecka J, Mahfoud F, Christ M, Hammerer-Lercher A, Breidthardt T, Mueller C.   +23 more
europepmc   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

N-terminal pro-B-type natriuretic peptide levels in pregnant women with heart disease and complications: A cohort study. [PDF]

Int J Reprod Biomed
Hatamian Z, Vahed SHM, Vakilian F, Poorzand H, Lotfalizade M, Zirak N, Majd HM, Nozari M, Dadgar S, Afiat M.   +9 more
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Association of Long-Term Oral β-Blocker Use With Cardiac Troponin I and B-Type Natriuretic Peptide in Septic Myocardial Injury: A Retrospective Cohort Study. [PDF]

Health Sci Rep
Yang Z, Jiang A, Zhu Y, Cao K, Meng J, Han F, Yang C.   +6 more
europepmc   +1 more source